Pharmacogenetics of development of inhibitory antibodies to factor VIII hemophilia A

Detalhes bibliográficos
Autor(a) principal: de Souza, Thiago Barbosa
Data de Publicação: 2011
Outros Autores: Duarte, Laura Pessanha, Souto Filho, João Tadeu Damian, Fernandez, Jorge Hernandez, Medina-Acosta, Enrique
Tipo de documento: Artigo
Idioma: por
Título da fonte: Revista Científica da Faculdade de Medicina de Campos
Texto Completo: https://www.fmc.br/ojs/index.php/RCFMC/article/view/106
Resumo: The most serious complication of factor VIII (FVIII) replacement therapy in patients with hemophilia A is the development of inhibitory alloantibodies or autoantibodies. The inhibitory antibodies impair effective hemostasis, representing real risk for hemorrhagic episodes difficult to control. This revision addresses the pertinent concepts, and covers the following pharmacogenetic aspects of the development of inhibitory antibodies: antibody types, inhibitory mechanisms, diagnostics, genetic and non-genetic risks factors, alternatives of treatment and intervention.
id FMC-0_ddfc598409fb071fff78fae553eb1868
oai_identifier_str oai:ojs.www.fmc.br:article/106
network_acronym_str FMC-0
network_name_str Revista Científica da Faculdade de Medicina de Campos
repository_id_str
spelling Pharmacogenetics of development of inhibitory antibodies to factor VIII hemophilia AFarmacogenética do desenvolvimento de anticorpos inibidores do fator VIII na hemofilia Afator VIIIhemofilia Ainibidoresresposta imunefactor VIIIhemophilia Ainhibitorsimmune responseThe most serious complication of factor VIII (FVIII) replacement therapy in patients with hemophilia A is the development of inhibitory alloantibodies or autoantibodies. The inhibitory antibodies impair effective hemostasis, representing real risk for hemorrhagic episodes difficult to control. This revision addresses the pertinent concepts, and covers the following pharmacogenetic aspects of the development of inhibitory antibodies: antibody types, inhibitory mechanisms, diagnostics, genetic and non-genetic risks factors, alternatives of treatment and intervention.A complicação mais séria da terapia de reposição do fator VIII (FVIII) nos pacientes com Hemofilia A é o desenvolvimento de aloanticorpos ou autoanticorpos inibidores. Os anticorpos inibidores impedem hemostasia efetiva, representando risco real para episódios hemorrágicos de difícil controle. Esta revisão aborda os conceitos pertinentes e cobre os seguintes aspectos farmacogenéticos do desenvolvimento de anticorpos inibidores: tipos de anticorpos, mecanismos de inibição, diagnóstico, fatores genéticos e não-genéticos de risco, alternativas de tratamento e de intervenção.Faculdade de Medicina de Campos (FMC)2011-07-01info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfhttps://www.fmc.br/ojs/index.php/RCFMC/article/view/10610.29184/1980-7813.rcfmc.106.vol.6.n1.2011Scientific Journal of the Medical School of Campos; Vol. 6 No. 1 (2011); 07-13Revista Científica da Faculdade de Medicina de Campos; v. 6 n. 1 (2011); 07-131980-7813reponame:Revista Científica da Faculdade de Medicina de Camposinstname:Faculdade de Medicina de Campos (FMC)instacron:FMCporhttps://www.fmc.br/ojs/index.php/RCFMC/article/view/106/83Copyright (c) 2011 Revista Científica da Faculdade de Medicina de Camposinfo:eu-repo/semantics/openAccessde Souza, Thiago BarbosaDuarte, Laura PessanhaSouto Filho, João Tadeu DamianFernandez, Jorge HernandezMedina-Acosta, Enrique2017-08-07T22:30:31Zoai:ojs.www.fmc.br:article/106Revistahttps://www.fmc.br/ojs/index.php/RCFMC/PRIhttps://www.fmc.br/ojs/index.php/RCFMC/oai||revista@fmc.br1980-78131980-7813opendoar:2017-08-07T22:30:31Revista Científica da Faculdade de Medicina de Campos - Faculdade de Medicina de Campos (FMC)false
dc.title.none.fl_str_mv Pharmacogenetics of development of inhibitory antibodies to factor VIII hemophilia A
Farmacogenética do desenvolvimento de anticorpos inibidores do fator VIII na hemofilia A
title Pharmacogenetics of development of inhibitory antibodies to factor VIII hemophilia A
spellingShingle Pharmacogenetics of development of inhibitory antibodies to factor VIII hemophilia A
de Souza, Thiago Barbosa
fator VIII
hemofilia A
inibidores
resposta imune
factor VIII
hemophilia A
inhibitors
immune response
title_short Pharmacogenetics of development of inhibitory antibodies to factor VIII hemophilia A
title_full Pharmacogenetics of development of inhibitory antibodies to factor VIII hemophilia A
title_fullStr Pharmacogenetics of development of inhibitory antibodies to factor VIII hemophilia A
title_full_unstemmed Pharmacogenetics of development of inhibitory antibodies to factor VIII hemophilia A
title_sort Pharmacogenetics of development of inhibitory antibodies to factor VIII hemophilia A
author de Souza, Thiago Barbosa
author_facet de Souza, Thiago Barbosa
Duarte, Laura Pessanha
Souto Filho, João Tadeu Damian
Fernandez, Jorge Hernandez
Medina-Acosta, Enrique
author_role author
author2 Duarte, Laura Pessanha
Souto Filho, João Tadeu Damian
Fernandez, Jorge Hernandez
Medina-Acosta, Enrique
author2_role author
author
author
author
dc.contributor.author.fl_str_mv de Souza, Thiago Barbosa
Duarte, Laura Pessanha
Souto Filho, João Tadeu Damian
Fernandez, Jorge Hernandez
Medina-Acosta, Enrique
dc.subject.por.fl_str_mv fator VIII
hemofilia A
inibidores
resposta imune
factor VIII
hemophilia A
inhibitors
immune response
topic fator VIII
hemofilia A
inibidores
resposta imune
factor VIII
hemophilia A
inhibitors
immune response
description The most serious complication of factor VIII (FVIII) replacement therapy in patients with hemophilia A is the development of inhibitory alloantibodies or autoantibodies. The inhibitory antibodies impair effective hemostasis, representing real risk for hemorrhagic episodes difficult to control. This revision addresses the pertinent concepts, and covers the following pharmacogenetic aspects of the development of inhibitory antibodies: antibody types, inhibitory mechanisms, diagnostics, genetic and non-genetic risks factors, alternatives of treatment and intervention.
publishDate 2011
dc.date.none.fl_str_mv 2011-07-01
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv https://www.fmc.br/ojs/index.php/RCFMC/article/view/106
10.29184/1980-7813.rcfmc.106.vol.6.n1.2011
url https://www.fmc.br/ojs/index.php/RCFMC/article/view/106
identifier_str_mv 10.29184/1980-7813.rcfmc.106.vol.6.n1.2011
dc.language.iso.fl_str_mv por
language por
dc.relation.none.fl_str_mv https://www.fmc.br/ojs/index.php/RCFMC/article/view/106/83
dc.rights.driver.fl_str_mv Copyright (c) 2011 Revista Científica da Faculdade de Medicina de Campos
info:eu-repo/semantics/openAccess
rights_invalid_str_mv Copyright (c) 2011 Revista Científica da Faculdade de Medicina de Campos
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv Faculdade de Medicina de Campos (FMC)
publisher.none.fl_str_mv Faculdade de Medicina de Campos (FMC)
dc.source.none.fl_str_mv Scientific Journal of the Medical School of Campos; Vol. 6 No. 1 (2011); 07-13
Revista Científica da Faculdade de Medicina de Campos; v. 6 n. 1 (2011); 07-13
1980-7813
reponame:Revista Científica da Faculdade de Medicina de Campos
instname:Faculdade de Medicina de Campos (FMC)
instacron:FMC
instname_str Faculdade de Medicina de Campos (FMC)
instacron_str FMC
institution FMC
reponame_str Revista Científica da Faculdade de Medicina de Campos
collection Revista Científica da Faculdade de Medicina de Campos
repository.name.fl_str_mv Revista Científica da Faculdade de Medicina de Campos - Faculdade de Medicina de Campos (FMC)
repository.mail.fl_str_mv ||revista@fmc.br
_version_ 1798042301405069312

Registros relacionados